Intech Investment Management LLC Invests $280,000 in Amedisys, Inc. (NASDAQ:AMED)

Intech Investment Management LLC acquired a new position in shares of Amedisys, Inc. (NASDAQ:AMED) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,054 shares of the health services provider’s stock, valued at approximately $280,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Banque Cantonale Vaudoise bought a new position in shares of Amedisys during the 1st quarter worth about $60,000. Innealta Capital LLC bought a new position in shares of Amedisys during the 2nd quarter worth about $64,000. Covestor Ltd lifted its holdings in shares of Amedisys by 134.2% during the 1st quarter. Covestor Ltd now owns 780 shares of the health services provider’s stock worth $72,000 after acquiring an additional 447 shares during the period. Signaturefd LLC lifted its holdings in Amedisys by 88.2% during the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider’s stock valued at $104,000 after purchasing an additional 530 shares during the last quarter. Finally, GAM Holding AG bought a new position in Amedisys during the 2nd quarter valued at about $275,000. 94.36% of the stock is owned by institutional investors.

Amedisys Trading Down 0.5 %

AMED opened at $96.63 on Friday. The company has a current ratio of 1.16, a quick ratio of 1.16 and a debt-to-equity ratio of 0.30. The stock has a market capitalization of $3.16 billion, a PE ratio of -150.98, a PEG ratio of 1.90 and a beta of 0.78. Amedisys, Inc. has a 1-year low of $89.55 and a 1-year high of $98.95. The firm has a 50-day moving average price of $97.61 and a two-hundred day moving average price of $94.97.

Amedisys (NASDAQ:AMED) last posted its quarterly earnings data on Wednesday, July 24th. The health services provider reported $1.32 earnings per share for the quarter, beating the consensus estimate of $1.22 by $0.10. The firm had revenue of $591.19 million during the quarter, compared to analysts’ expectations of $579.34 million. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. As a group, equities analysts anticipate that Amedisys, Inc. will post 4.66 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. William Blair downgraded shares of Amedisys from an “outperform” rating to a “market perform” rating in a report on Monday, July 1st. Cantor Fitzgerald reissued a “neutral” rating and set a $101.00 price target on shares of Amedisys in a report on Thursday, July 25th. Finally, Deutsche Bank Aktiengesellschaft downgraded shares of Amedisys from a “buy” rating to a “hold” rating and set a $101.00 price target for the company. in a report on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $100.67.

Amedisys Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.